-
Jun 4, 2012, 00:00 AM
by
Michael Croft
Xconomy | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen.
Full story
-
Jun 1, 2012, 01:00 AM
by
Michael Croft
Bio-IT World | News briefs and bits from the biotech industry in May.
Full story
-
May 31, 2012, 09:20 AM
by
Michael Croft
Bio-IT World | The long-term success of cancer informatics company N-of-One will be shaped by its newly appointed CEO, strategic partnerships with companies like Foundation Medicine, and ultimately the experiences of cancer patients such as Elaine Waples.
Full story
-
May 31, 2012, 02:00 AM
by
Michael Croft
Bio-IT World | BOULDER, CO—Larry Gold, the founder and CEO of protein biomarker company SomaLogic, hosted a diverse and engaging group of speakers for the third annual GoldLab Symposium* on the future of health care and personalized medicine earlier this month. “Technology is only the penultimate step in successful innovation,” he said.
Full story
-
May 31, 2012, 01:00 AM
by
Michael Croft
Mass High Tech | Ensemble Therapeutics and Genentech are collaborating on macrocyclic drug candidates against targets identified by Genentech. The companies will use the Ensemblin collection of macrocycles and Ensemble's proprietary drug discovery platform.
Full story
-
May 31, 2012, 00:00 AM
by
Michael Croft
CNBC | GlaxoSmithKline is hoping to replace the board of Human Genome Sciences with its own representatives, reaching out to executives who could be nominated as "independent" directors.
Full story
-
May 30, 2012, 04:00 AM
by
Michael Croft
Bio-IT World | Foundation Medicine has announced the commercial launch of FoundationOne, the first pan-cancer, fully informative genomic profile designed to help oncologists expand their patients’ treatment options.
Full story
-
May 30, 2012, 00:05 AM
by
Michael Croft
Texas Advanced Computing Center | Drug discovery with 3D help may be a lot more efficient than traditional methods. Researchers at the University of Texas at Austin's Computational Visualization Center have attacked each step of the drug discovery process.
Full story
-
May 30, 2012, 00:00 AM
by
Michael Croft
Nature | The HudsonAlpha Institute in Huntsville, Ala. is hosting a conference covering immunology, genomics, bioinformatics, and clinical interactions.
Full story
-
May 29, 2012, 05:00 AM
by
Michael Croft
eCliniqua | The role of cost and patients in comparative effectiveness research (CER) were among the themes of a Post-Approval Summit held earlier this month at Harvard Medical School*. So, too, was the agenda and funding priorities of the latest actor in the CER arena: the independent, multi-stakeholder Patient-Centered Outcomes Research Institute (PCORI).
Full story
-
May 29, 2012, 03:00 AM
by
Michael Croft
The Spittoon | 23andMe CEO and co-founder Anne Wojcicki has announced the company's first patent, expected today: “Polymorphisms Related to Parkinson’s Disease.” The patent relates to the company's discovery of a variant in the SGK1 gene that may be protective against individuals at high risk of Parkinson's thanks to the rare LRRK2 G2019S mutation.
Full story
-
May 29, 2012, 02:05 AM
by
Michael Croft
Bio-IT World | Researchers focusing on Asian cancers have used whole-genome sequencing to study the level of hepatitis B virus integration in the genomes of cancer patients and to discover three novel genes associated with recurrent hepatitis B virus integration in hepatocellular carcinoma. The study was published today in Nature Genetics.
Full story
-
May 29, 2012, 02:00 AM
by
Michael Croft
Bio-IT World | A summary of the new products in bio-IT released in the past month including NGS sample prep, cloud storage-as-a-service, clinical trial document management, and more.
Full story
-
May 25, 2012, 03:00 AM
by
Michael Croft
Winnipeg Free Press | Canadian researchers screened about 3,000 compounds looking for those that would selectively inhibit cancer stem cells. Of the 20 promising results, one was the antipsychotic drug thioridazine.
Full story
-
May 24, 2012, 07:00 AM
by
Michael Croft
Bio-IT World | The Singapore National Research Foundation (NRF) Fellowship has released the call for applicants for the sixth annual Singapore NRF Fellowship. The fellowship consists of a five-year research grant of up to $2.4 million to an individual, for research undertaken in Singapore. Fellowship proposals are due by August 15, 2012.
Full story
-
May 24, 2012, 02:00 AM
by
Michael Croft
Bloomberg | In light of a small set of data, Amgen is reviving its gastric cancer drug rilotumumab that seems to show efficacy for patients with high levels of c-Met, a protein linked to cancer growth. The revival is a win for personalized medicine.
Full story
-
May 24, 2012, 01:00 AM
by
Michael Croft
Xconomy | Ra Pharmaceuticals is announcing its technology platform to develop protein-like molecules that it calls Cyclomimetrics. The technology was licensed from Uppsala University in Sweden, and makes large molecules that can be made into pills.
Full story
-
May 24, 2012, 01:00 AM
by
Michael Croft
CNN | The American College of Obstetricians and Gynecologists released its recommendation this week that personalized genetic tests be only used in a clinical trial setting, saying the tests are not "ready for prime time."
Full story
-
May 23, 2012, 18:00 PM
by
Michael Croft
Bio-IT World | With a recent rebranding and evolving business model, Selventa—the company formerly known as Genstruct—has decided to release a key knowledge engineering asset to the scientific community.
Full story
-
May 23, 2012, 04:00 AM
by
Michael Croft
New York Times | Genentech's new Alzheimer's drug trial will test the drug on 200 patients with a genetic mutation for early-onset disease (with half receiving placebo) and another 100 family members without the mutation.
Full story
